ClinicalTrials.gg
TerminatedNCT04130438Updated Feb 25, 2025Results posted

Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging

A Phase 2 interventional study of Nebivolol and Diltiazem in Myocardial Bridging, sponsored by Stanford University. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Stanford University · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Low recruitment, insufficient funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The proposed clinical trial is relevant to public health because it is expected to expand the differential diagnosis and provide an evidence--based therapy for the large population of patients with angina in the absence of obstructive CAD who currently remain undiagnosed and untreated. It, therefore, upholds an important part of the mission of the The National Heart, Lung, and Blood Institute (NHLBI), which is to promote the treatment of heart disease and enhance the health of all individuals so that they can live longer and more fulfilling lives.

Read the detailed description

Angina in the absence of obstructive coronary artery disease (CAD) affects millions, resulting in a reduced quality of life and a burden on the health care system. Previous work has focused on endothelial and microvascular dysfunction as causes of angina in these patients, but even when these etiologies are tested for, nearly half of patients remain undiagnosed, and proven therapies are lacking. The long--term goal of this research proposal is to improve the lives of patients with angina in the absence of obstructive CAD. These patients have been found to have a disproportionate prevalence of myocardial bridges (MBs) (60% vs. 30% in the general population).

MBs are known to cause angina, and the mechanism by which they do so is also known, but MBs have not been actively studied in the context of patients with angina in the absence of obstructive CAD. Medical therapies for symptomatic MBs, including beta blockers and calcium channel blocker have been suggested, but have never been appropriately tested, and may not be better than placebo. The overall objective of this research proposal is to demonstrate that MBs are an important and treatable cause of angina in patients with non--obstructive CAD.

The investigator will conduct the first--ever randomized, double--blind, placebo--controlled trial of medical therapy in patients with angina and an MB. The rationale is that a proven treatment would significantly expand the paradigm by which patients with angina in the absence of obstructive CAD are evaluated and treated. Our central hypothesis is that beta blockers and calcium channel blockers are effective treatments for reducing angina in patients with an MB compared with placebo. Guided by strong preliminary data, this hypothesis will be tested by pursuing two specific aims: 1) Determine the efficacy of beta blockers and calcium channel blockers in treating patients with angina and an MB and 2) Identify predictors of efficacy of beta blockers and calcium channel blockers in treating patients with angina and an MB. For Aim #1, the investigator will randomize a total of 360 adult patients with angina and an MB into one of three treatment arms: beta blocker (nebivolol), calcium channel blocker (diltiazem), or placebo (1:1:1).

Efficacy will be determined after 30 days on the study drug by a change in angina, as assessed by the Seattle Angina Questionnaire (SAQ). The investigator will also evaluate changes in exercise capacity, as well as drug adherence and side effects. For Aim #2, the investigator will evaluate MB muscle index (MMI, a product of MB length x depth) by coronary computed tomography angiography, as well as male sex, as predictors of efficacy. Randomization will be stratified on sex, ensuring a balance of women and men in each arm. The proposed research is innovative because it shifts the current clinical perspective on angina in the absence of obstructive CAD by considering myocardial bridging as a potential etiology.

It is also significant because it will substantially increase the number of patients with angina in the absence of obstructive CAD that clinicians are able to diagnose and treat, ultimately leading to improvements in quality of life and a reduction in health care costs.

02

Conditions studied

  • Myocardial Bridging
03

In context

Lead sponsor

Stanford University is the lead sponsor of 2,173 studies on the registry; 433 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Stable angina (typical or atypical, based on Diamond criteria (35))
  3. Exercise stress echocardiogram or exercise stress test (with beta blocker or calcium channel blocker held) performed within six months of enrollment
  4. CCTA or invasive coronary angiogram confirming the presence of an MB
  5. Absence of obstructive CAD, as demonstrated by no ischemia on stress testing and no significant obstructive CAD (coronary stenosis \<50%) on CCTA or invasive coronary angiogram

Exclusion criteria

Exclusion Criteria:

  1. Asymptomatic
  2. Status--post heart transplant
  3. Presence of another likely explanation of chest pain, such as pulmonary hypertension, hypertrophic obstructive cardiomyopathy, or aortic stenosis
  4. Presence of an acute coronary syndrome (unstable angina, NSTEMI, or STEMI), Tako--tsubo, or cardiogenic shock
  5. An abnormal (EF\<55%)
  6. History of a severe adverse reaction to beta blockers or calcium channel blockers (prior minor intolerance or ineffectiveness not exclusion)
  7. Use of existing medication that has an unsafe drug--drug interaction with beta blockers or calcium channel blockers
  8. Refusal to take beta blockers or calcium channel blockers
  9. Resting systolic blood pressure \<100 mmHg or heart rate \<50 beats per minute
  10. Inability to provide an , including an inability to speak, read, or understand English or Spanish
  11. A hearing impairment that won't allow for a typical verbal conversation or a visual impairment that won't allow for reading of the written consent
  12. A potentially vulnerable subject (including pregnant women, prisoners, economically and educationally disadvantaged, decisionally impaired, and institutionalized individuals)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
5 participants (actual)

Study arms

  • Active comparator
    Beta Blocker (nebivolol)

    Drug: Nebivolol

  • Active comparator
    Calcium Channel Blocker (diltiazem)

    Drug: Diltiazem

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.

  • The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.

  • OtherPlacebo

    The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.

06

What researchers measure

Primary outcomes

  1. Change in Angina Score Assessed by the Seattle Angina Questionnaire (SAQ)

    Effectiveness of beta blockers and calcium channel blockers for reducing angina in patients with a Myocardial Bridge (MB) compared to placebo determined after 30 days on the study drug by a change in angina, as assessed by the Seattle Angina Questionnaire (SAQ). The SAQ assesses 5 domains: physical limitation, angina stability angina frequency, treatment satisfaction, and quality of life. Each domain score is normalized to a range of 0 to 100, with higher scores corresponding to better outcomes.

    Time frame: baseline and 30 days

Secondary outcomes

  1. Duke Treadmill Score by Risk Category

    Changes in exercise capacity will be measured by difference in exercise time increment between the groups. The Duke treadmill score is calculated as exercise time × (5 × ST-segment deviation) - (4 × exercise angina), with 0 = no angina, 1 = non-limiting angina, and 2 = exercise-limiting angina. Possible scores range from -25 (highest risk) to +15 (lowest risk). Scores are reported by the number of participants in each risk category: low risk (≥+5), moderate risk (-10 to +4) and high risk (≤-11) (Shaw, et al, 1998).

    Time frame: baseline, 30 days

  2. Duke Treadmill Score

    The Duke treadmill score is calculated as exercise time × (5 × ST-segment deviation) - (4 × exercise angina), with 0 = no angina, 1 = non-limiting angina, and 2 = exercise-limiting angina. Possible scores range from -25 (highest risk) to +15 (lowest risk).

    Time frame: baseline, 30 days

  3. Number of Participants With Cardiac Events

    Major adverse cardiovascular events include death, heart attack, coronary stent or bypass surgery, and stroke.

    Time frame: 30 days, 6 months

  4. Drug Adherence.

    Percentage of drug taken by participants, measured by pill count at the end of 30 days.

    Time frame: 30 days

  5. Number of Participants With Side Effects

    Patient self-reported side effects recorded in a diary to be turned in at 30 days. In addition, patients are requested to contact us regarding any serious side effects during the study. Finally, patients are asked about any side effects they experienced during their 30-day follow-up to ensure that symptoms are captured.

    Time frame: 30 days

  6. Treatment Course

    Number of participants who stayed on the study drug at the initial dose, stayed on the study drug at a different dose, switched to an alternate therapy, and/or underwent further cardiac testing.

    Time frame: 6 months

07

Results

Posted Feb 25, 2025
Limitations and caveats
Early termination led to a small number of subjects analyzed.

Participant flow

Participant flow — Overall Study
MilestoneBeta Blocker (Nebivolol)Calcium Channel Blocker (Diltiazem)Placebo
Started212
Had at least 1 post-baseline visit211
Completed211
Not completed001
Withdrew: Lost to follow-up001

Outcome measures

PrimaryChange in Angina Score Assessed by the Seattle Angina Questionnaire (SAQ)

Effectiveness of beta blockers and calcium channel blockers for reducing angina in patients with a Myocardial Bridge (MB) compared to placebo determined after 30 days on the study drug by a change in angina, as assessed by the Seattle Angina Questionnaire (SAQ). The SAQ assesses 5 domains: physical limitation, angina stability angina frequency, treatment satisfaction, and quality of life. Each domain score is normalized to a range of 0 to 100, with higher scores corresponding to better outcomes.

Time frame:
baseline and 30 days
Reported as:
Mean · score on a scale
Change in Angina Score Assessed by the Seattle Angina Questionnaire (SAQ)
score on a scaleBeta Blocker (Nebivolol)Calcium Channel Blocker (Diltiazem)Placebo
Physical limitation - baseline44.4 ± 24.462.2 ± NA53.4 ± 15.6
Physical limitation - 30 days53.6 ± 24.568.0 ± NA17.8 ± NA
Angina stability - baseline40 ± 040 ± NA80 ± 20
Angina stability - 30 days50 ± 3060 ± NA20 ± 0
Angina frequency - baseline70 ± 060 ± NA75 ± 25
Angina frequency - 30 days80 ± 1080 ± NA30 ± NA
Treatment satisfaction - baseline67.7 ± 8.9100 ± NA76.5 ± 5.85
Treatment satisfaction - 30 days64.7 ± 11.894.1 ± NA29.4 ± NA
Quality of life - baseline41.6 ± 2541.7 ± NA37.5 ± 20.9
Quality of life - 30 days54.1 ± 20.958.3 ± NA25 ± NA
SecondaryDuke Treadmill Score by Risk Category

Changes in exercise capacity will be measured by difference in exercise time increment between the groups. The Duke treadmill score is calculated as exercise time × (5 × ST-segment deviation) - (4 × exercise angina), with 0 = no angina, 1 = non-limiting angina, and 2 = exercise-limiting angina. Possible scores range from -25 (highest risk) to +15 (lowest risk). Scores are reported by the number of participants in each risk category: low risk (≥+5), moderate risk (-10 to +4) and high risk (≤-11) (Shaw, et al, 1998).

Time frame:
baseline, 30 days
Reported as:
Count of participants · Participants
Duke Treadmill Score by Risk Category
ParticipantsBeta Blocker (Nebivolol)Calcium Channel Blocker (Diltiazem)Placebo
Low risk - baseline000
Moderate risk - baseline212
High risk - baseline000
Low risk - 30 days010
Moderate risk - 30 days100
High risk - 30 days001
SecondaryDuke Treadmill Score

The Duke treadmill score is calculated as exercise time × (5 × ST-segment deviation) - (4 × exercise angina), with 0 = no angina, 1 = non-limiting angina, and 2 = exercise-limiting angina. Possible scores range from -25 (highest risk) to +15 (lowest risk).

Time frame:
baseline, 30 days
Reported as:
Mean · score on a scale
Duke Treadmill Score
score on a scaleBeta Blocker (Nebivolol)Calcium Channel Blocker (Diltiazem)Placebo
Baseline2.3 ± 2.353.0 ± NA1.5 ± 4.95
30 days2 ± NA10 ± NA-11 ± NA
SecondaryNumber of Participants With Cardiac Events

Major adverse cardiovascular events include death, heart attack, coronary stent or bypass surgery, and stroke.

Time frame:
30 days, 6 months
Reported as:
Count of participants · Participants
Number of Participants With Cardiac Events
ParticipantsBeta Blocker (Nebivolol)Calcium Channel Blocker (Diltiazem)Placebo
30 days000
6 months000
SecondaryDrug Adherence.

Percentage of drug taken by participants, measured by pill count at the end of 30 days.

Time frame:
30 days
Reported as:
Mean · percentage of drug taken
Drug Adherence.
percentage of drug takenBeta Blocker (Nebivolol)Calcium Channel Blocker (Diltiazem)Placebo
Drug Adherence.99.5 ± 0.5100 ± NA100 ± NA
SecondaryNumber of Participants With Side Effects

Patient self-reported side effects recorded in a diary to be turned in at 30 days. In addition, patients are requested to contact us regarding any serious side effects during the study. Finally, patients are asked about any side effects they experienced during their 30-day follow-up to ensure that symptoms are captured.

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Participants With Side Effects
ParticipantsBeta Blocker (Nebivolol)Calcium Channel Blocker (Diltiazem)Placebo
Number of Participants With Side Effects000
SecondaryTreatment Course

Number of participants who stayed on the study drug at the initial dose, stayed on the study drug at a different dose, switched to an alternate therapy, and/or underwent further cardiac testing.

Time frame:
6 months
Reported as:
Count of participants · Participants
Treatment Course
ParticipantsBeta Blocker (Nebivolol)Calcium Channel Blocker (Diltiazem)Placebo
Stayed on study drug at the initial dose200
Stayed on study drug at a different dose010
Switched to alternate therapy001
Underwent further cardiac testing000

Adverse events

Collected over Up to 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Beta Blocker (Nebivolol)0/2 (0%)0/2 (0%)0/2 (0%)
Calcium Channel Blocker (Diltiazem)0/1 (0%)0/1 (0%)0/1 (0%)
Placebo0/2 (0%)0/2 (0%)0/2 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Beta Blocker (Nebivolol)Calcium Channel Blocker (Diltiazem)PlaceboTotal
<=18 years0000
Between 18 and 65 years2125
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Beta Blocker (Nebivolol)Calcium Channel Blocker (Diltiazem)PlaceboTotal
Female2013
Male0112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Beta Blocker (Nebivolol)Calcium Channel Blocker (Diltiazem)PlaceboTotal
Hispanic or Latino0000
Not Hispanic or Latino1124
Unknown or Not Reported1001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Beta Blocker (Nebivolol)Calcium Channel Blocker (Diltiazem)PlaceboTotal
Asian0022
White1001
Other1102
Region of Enrollment
Region of Enrollment(Participants)Beta Blocker (Nebivolol)Calcium Channel Blocker (Diltiazem)PlaceboTotal
United States2125
08

Study locations

1 site
  • Stanford University
    Stanford, California 94305, United States
09

References and documents

Publications

  • Shaw LJ, Peterson ED, Shaw LK, Kesler KL, DeLong ER, Harrell FE Jr, Muhlbaier LH, Mark DB. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. Circulation. 1998 Oct 20;98(16):1622-30. doi: 10.1161/01.cir.98.16.1622. PubMed 9778327 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Mar 2022, 16 months.

Results were first posted in Feb 2025, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2019
First posted
Oct 17, 2019
StartActual
Oct 15, 2020
Primary completionActual
Mar 11, 2022
CompletionActual
Oct 17, 2024
Results first posted
Feb 25, 2025
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04130438
Responsible party
Jennifer A Tremmel, MD, MS (Interventional cardiologist, Stanford University) — Principal investigator
First posted
Oct 17, 2019
Start date
Oct 15, 2020
Primary completion
Mar 11, 2022
Completion
Oct 17, 2024
Results posted
Feb 25, 2025
Last update
Feb 25, 2025

Study contacts

Jennifer Tremmel, MD, MS
principal investigator · Stanford University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nebivolol · Diltiazem

Start the discussion